– SWITZERLAND, St Gallen – Vifor Pharma (SWX: VIFN) today announced the nomination of Åsa Riisberg for election to its Board of Directors at the AGM on 6 May 2021.
“We are very pleased that Åsa Riisberg will bring her expertise to the Board of Directors. Her broad knowledge and experience, particularly in the areas of investment management and operations are extremely valuable for Vifor Pharma. She will ideally complement the Board to assess the company’s business development and inorganic growth plans, aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.” said Board Chairman, Jacques Theurillat.
About Åsa Riisberg
Åsa Riisberg, a Swedish citizen, was formerly a Partner and member of the extended Executive Committee of the private equity firm EQT. She has served on various international boards with current board seats at Atlas Antibodies, Netcompany, F-Secure, Dagens Nyheter, Bonnier News, and Bonnier Capital as well as at the Women in Finance Foundation. Åsa is also an Advisory Board Member at the Stockholm School of Economics and member of the Investment Committee at Cinder Invest.
She holds an M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
About Vifor Pharma
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology, and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures, and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
Vifor Pharma Group is headquartered in Switzerland, and is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.